SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Higuchi Ichiyō

PatientHiguchi Ichiyō
Date of birth2002-05-02
IdentifiersMRN HR-NI029-SYN; SSN (made up) 000-29-5108
Document date2026-10-20
AuthorAiko Lindgren-Tanaka, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

End-of-treatment review after six months. [S]

History of Present Illness

Ms. Higuchi returns having completed treatment five days ago: all 182 doses were observed by video, 56 in the intensive phase and 126 in the continuation phase, with none missed. The two-month sputum culture showed no growth. She has had no cough, fever or night sweats for four months and has gained 5.5 kg since intake. She has had no nausea, yellowing, numbness or change in vision. The cystitis in the summer did not return. The public health center has told her that its contact investigation is complete. She writes each morning and has finished two stories since the summer. Her cervical cytology was normal. [S]

ElementDetail
Treatment182 of 182 doses observed; completed five days ago
BacteriologyTwo-week and two-month cultures negative
Weight44.0 kg, up 5.5 kg from intake
WritingTwo new stories finished

Review of Systems

SystemResultFinding
RespiratoryNegativeNo cough, sputum or breathlessness
ConstitutionalNegativeNo fever, night sweats or weight loss
GastrointestinalNegativeNo nausea or jaundice
NeurologicalNegativeNo numbness or tingling
PsychiatricNegativeMood good; PHQ-9 3

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 100 mg tablets, two tablets (200 mg) daily200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route2026-04-17 to 2026-10-15completedS
Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route2026-04-17 to 2026-10-15completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phaseOral route2026-04-17 to 2026-06-11completedS
Ethambutol 100 mg tablets, six tablets (600 mg) daily600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results returnOral route2026-04-17 to 2026-05-22stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route2026-04-17 to 2026-10-15completedS
Nitrofurantoin monohydrate/macrocrystals 100 mg oral capsule, one capsule twice daily with food for five daysOne capsule twice daily with food for five daysOral route2026-07-20 to 2026-07-24completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-20Body height148cmS
2026-10-20Body weight44kgS
2026-10-20Body mass index (BMI) [Ratio]20.1kg/m2S
2026-10-20Systolic blood pressure106mm[Hg]S
2026-10-20Diastolic blood pressure68mm[Hg]S
2026-10-20Heart rate72/minS
2026-10-20Respiratory rate14/minS
2026-10-20Body temperature36.5CelS
2026-10-20Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-35 U/LNormalS
2026-10-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L10-35 U/LNormalS
2026-10-20Albumin [Mass/volume] in Serum or Plasma4.2g/dL3.5-5 g/dLNormalS
2026-10-20Hemoglobin [Mass/volume] in Blood13.2g/dL12-15.5 g/dLNormalS
2026-10-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 2026-10-20; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 44.0 kg, BMI 20.1; temperature 36.5 °C, pulse 72, blood pressure 106/68
EyesNo icterus
RespiratoryClear on both sides
AbdomenSoft; liver not enlarged
NeurologicalNormal sensation and reflexes in the feet

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and cultureresolvedconfirmed R05.3S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D).
Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected)resolvedconfirmed A15.0S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic.
Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dLresolvedconfirmed E44.0S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty.
Low and irregular income from writing, with a household to support; costs of care are a barrieractiveconfirmed Z59.6S — Synthetic social need anchored to her documented poverty and household responsibilities.
Acute uncomplicated cystitis, treated with nitrofurantoin rather than a fluoroquinolone during tuberculosis treatment; resolvedresolvedconfirmed N30.00S — Synthetic intercurrent illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptom review: cough, sputum, fever, night sweatsAt least monthly during treatmentCompleted todayNo symptoms for four months
Self-managementWeight and nutritionEvery visit; dose review if weight changes by more than about 5 kgCompleted today44.0 kg, BMI 20.1; albumin 4.2 g/dL
Medication safetyHepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine)Every visit and every observed doseCompleted todayNo symptoms throughout the continuation phase
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptomsCompleted todayALT 18, AST 20 U/L at the end of treatment; no tests were needed for symptoms in the continuation phase
LaboratoryTwo-month sputum smear and cultureAt the end of the intensive phaseCompleted todaySmear negative; no growth at six weeks, as with the two-week culture
LaboratoryBlood countAt diagnosis, then as neededCompleted todayHemoglobin 13.2 g/dL, normal
ImagingChest X-rayAt diagnosis and at the end of treatment as a new baselineCompleted todayOpacities cleared, with a few linear scars; new baseline
Medication safetyDoses observed and missed (video-observed therapy)Every visitCompleted today182 of 182 doses observed; treatment completed
Medication safetyPeripheral neuropathy check, with pyridoxineEvery visitCompleted todayNo neuropathy; pyridoxine stopped with isoniazid
ImagingVisual acuity and color visionBaseline and monthly while on ethambutolNot indicatedEthambutol stopped in the fifth week; acuity normal at two months
ReferralContact investigation (household and close contacts)Led by the public health center, from diagnosisCompleted todayThe public health center reports the investigation complete; results are held in the contacts' own records
ReferralReport of treatment outcome to the public health centerAt the end of treatmentCompleted todayTreatment completed reported
SurveyDepression screen (PHQ-9)At diagnosis, at two months, and at the end of treatmentCompleted todayPHQ-9 3, item 9 scored 0
Self-managementHepatitis B, HPV and influenza vaccinesHepatitis B in two doses four weeks or more apart; HPV in three doses; influenza each autumnCompleted todayHepatitis B dose 2 (series complete), HPV dose 2 and influenza vaccine given today; HPV dose 3 due in four months

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Human papillomavirus 9-valent vaccine, dose 2 of 3; Influenza vaccine, inactivated, trivalent, preservative-free [S]

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025); WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012); Depression and Suicide Risk in Adults: Screening (2023); Adult Immunization Schedule by Age (2026)

Follow-up: No routine tuberculosis follow-up; return for symptoms. HPV dose 3 in four months. Next preventive visit in about ten months. [S]